Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

13,292 total articles

Watts Water Technologies Director Disposes $2.47M in Class A Shares

Watts Water Technologies Director Disposes $2.47M in Class A Shares

Timothy P. Horne, a director at Watts Water Technologies Inc., sold 7,500 Class A Common Stock shares on February 20, 2026, for $2,475,300. The transaction occurred at prices between $330.00 and $330.90, compared with a listed share price of $323.10. Horne continues to hold 7,500 shares through a revocable trust. The company recently declared a qua…

Itron Senior VP Sells Shares to Cover RSU Taxes as Company Reports Strong Q4 and Plans Note Offering

Itron Senior VP Sells Shares to Cover RSU Taxes as Company Reports Strong Q4 and Plans Note Offering

Itron Inc. Senior Vice President, Device Solutions, Patrick Justin K sold 4,930 shares on February 19, 2026 to satisfy tax withholding obligations tied to a performance-based restricted stock unit award. The transaction totaled $490,724 and leaves him with 34,344 shares. The sale accounts for less than 0.01% of Itron's $4.41 billion market capitali…

Itron SVP Sells Shares to Cover Tax Withholding as Company Posts Strong Q4 and Files Convertible Note Offering

Itron SVP Sells Shares to Cover Tax Withholding as Company Posts Strong Q4 and Files Convertible Note Offering

Itron Inc. senior vice president and general counsel Christopher E. Ware sold 4,486 shares on February 19, 2026, at $99.5385 per share to satisfy tax withholding obligations associated with a performance-based restricted stock unit award. The transaction, disclosed in a Form 4 filing, left Ware with 31,806 shares. Separately, Itron reported fourth-…

Lexicon Director Acquires 150,000 Shares as Company Secures Financing and Moves Pilavapadin to Phase 3

Lexicon Director Acquires 150,000 Shares as Company Secures Financing and Moves Pilavapadin to Phase 3

Director Raymond Debbane purchased 150,000 shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) in two transactions on February 19-20, 2026. The buying occurred as the stock has risen 107% over the past year and follows a financing package of roughly $100 million. The FDA has cleared Lexicon's pilavapadin to advance to two Phase 3, placebo-controlled, …